Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
Provided herein are compositions comprising platelet derivatives, and methods for administering the same to a subject in need thereof. Also provided herein are methods and compositions for reducing bleeding in a subject. Such methods can include administering to the subject in need thereof, for example because they have been or are being treated with an anticoagulant agent, for example, a factor XI inhibitor, and/or an antiplatelet, a dose of rehydrated platelet derivative composition comprising platelet derivatives. Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
3.
METHODS OF ADMINISTERING PLATELET DERIVATIVE COMPOSITIONS TO REDUCE BLEEDING IN SUBJECTS REFRACTORY TO PLATELET TRANSFUSION
Provided herein are compositions, and methods for administering a platelet derivative composition for reducing bleeding in a subject who is refractory to platelet transfusion. Methods herein can further include administering a platelet derivative composition to a subject having low platelet counts (e.g., having thrombocytopenia) and/or to maintain the number of platelets over a threshold amount, or to increase the number of platelets in the subject. Methods herein can include administering a therapeutic agent before and optionally after administering the platelet derivative composition to the subject. Methods herein can reduce or eliminate any dosing and/or scheduling adjustments of a therapeutic regimen due to a low platelet count.
Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject having Hermansky Pudlak Syndrome (HPS) or Bernard Soulier Syndrome (BSS), comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. The platelet derivatives can have numerous characteristics provided herein, that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.
Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
The present disclosure provides processes for preparing cryopreserved platelets, compositions comprising frozen platelets in a cryopreservation medium, and a collection of cryo-vessels comprising cryopreserved platelets. In some aspects, provided herein are processes for preparing cryopreserved platelets from a platelet pool of more than 1 donor to provide collections of cryopreserved platelets with improved vial to vial and lot to lot consistency for example, in DMSO concentration. Also provided herein is a collection of cryo-vessels, each comprising cryopreserved platelets having a biomolecule profile indicative of more than 1 platelet donor. Furthermore, provided herein are compositions comprising frozen platelets that when stored at a temperature in a range of -10°C to -30°C, for at least 1 month are capable of yielding a platelet count of at least 1.0 x 1011/35 ml of the composition and other recited properties
Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject, comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. Such effective dose in illustrative embodiments, includes multiple individual doses, or a continuous dose administered within a time period, for example a time period of less than 4 hours. In certain aspects herein the subject is a subject having Hermansky Pudlak Syndrome (HPS). The platelet derivatives can have numerous characteristics provided herein that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors, and are HLA Class 1-characterized platelet derivatives (e.g., FDPDs), which in certain illustrative embodiments are HLA Class 1-matched FDPDs. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.
Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject, comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. Such effective dose in illustrative embodiments, includes multiple individual doses, or a continuous dose administered within a time period, for example a time period of less than 4 hours. In certain aspects herein the subject is a subject having Hermansky Pudlak Syndrome (HPS). The platelet derivatives can have numerous characteristics provided herein that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors, and are HLA Class 1-characterized platelet derivatives (e.g., FDPDs), which in certain illustrative embodiments are HLA Class 1-matched FDPDs. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.
Provided herein are materials and methods for the preparation of blood products. In some aspects, provided herein are compositions and collections of such compositions, that include populations of HLA-characterized (e.g., HLA-matched), freeze-dried platelet derivatives from more than 1 donor, methods of producing the same, as well as methods of using the same to treat a subject. Such methods include methods of selecting a batch of FDPDs to administer to a recipient, for example that has anti-HLA alloantibodies. Such freeze-dried platelet derivatives have improved properties, as disclosed herein.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
11.
Methods of treating bleeding in a subject treated with an antiplatelet agent
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
C12N 5/078 - Cellules du sang ou du système immunitaire
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder are disclosed, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
C12N 5/078 - Cellules du sang ou du système immunitaire
17.
PLATELET DERIVATIVE COMPOSITIONS FOR USE IN SUBJECTS AFFLICTED WITH HERMANSKY PUDLAK SYNDROME OR BERNARD SOULIER SYNDROME
Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject having Hermansky Pudlak Syndrome (HPS) and Bernard Soulier Syndrome (BSS), comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. The platelet derivatives can have numerous characteristics provided herein, that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
Provided herein is a composition of matter comprising dried blood plasma substantially free of blood cell components; and a) a resuscitative mixture comprising at least one saccharide, at least one salt, and at least one high molecular weight, non-ionic, hydrophilic polymer, b) platelets or platelet-derived material, or c) both a) and b).
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61K 31/7016 - Disaccharides, p. ex. lactose, lactulose
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/14 - Composés d'ammonium quaternaire, p. ex. édrophonium, choline
20.
THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 38/14 - Peptides contenant des radicaux saccharideLeurs dérivés
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
22.
PRODUCTS AND METHODS USING A PLATELET-DERIVED HEMOSTATIC AGENT FOR CONTROLLING BLEEDING AND IMPROVING HEALING
Compositions and methods for providing one or more platelet-derived hemostatic agents to a treatment site are provided. Compositions and methods may be directed to bandages, carrier materials, and closure devices. Compositions and methods may be directed to treatment of neoplasias, including cancers. The platelet-derived hemostatic agents may include chemotherapeutic agents.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
23.
Materials and methods for producing blood products
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
Provided herein are materials and methods for the preparation of blood products. In some aspects, provided herein are compositions that include populations of platelet derivatives, including freeze-dried platelet derivatives, methods of producing the same, as well as methods of using the same to treat a subject. Such platelet derivatives have improved properties, as disclosed herein.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
27.
PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING AND USING SUCH COMPOSITIONS
Provided herein are materials and methods for the preparation of blood products. In some aspects, provided herein are compositions that include populations of platelet derivatives, including freeze-dried platelet derivatives, methods of producing the same, as well as methods of using the same to treat a subject. Such platelet derivatives have improved properties, as disclosed herein.
The present disclosure provides dry and liquid compositions that include canine platelets and/or canine platelet-derived substances in dried form or rehydrated form from a dried form of canine platelets and/or canine platelet-derived substances, as well as processes for preparing such compositions. The disclosure also provides processes for making the compositions and methods of using the compositions for therapeutic, prophylactic, diagnostic, and research purposes, and kits comprising the compositions.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
C12N 5/078 - Cellules du sang ou du système immunitaire
29.
FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTICOAGULANT-INDUCED COAGULOPATHY
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
C12N 5/078 - Cellules du sang ou du système immunitaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
30.
FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET INDUCED COAGULOPATHY
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.
In some embodiments provided herein is a method of treating a coagulopathy in a subject that is being administered or has been administered an antiplatelet agent, the method comprising: (a) determining that the subject has an abnormal result for evaluation of one or more clotting parameters; and (b) after (a), administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C12N 5/078 - Cellules du sang ou du système immunitaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
G01N 33/96 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
35.
FREEZE-DRIED PERIPHERAL BLOOD MONONUCLEAR CELL COMPOSITIONS AND METHODS
Provided herein are methods of preserving PBMCs, including lyophilizing PBMCs, and compositions thereof. In some embodiments, such compositions include freeze-dried or rehydrated PBMCs in an aqueous mixture comprising a cryoprotectant, a lyoprotectant, and a buffer. In some embodiments, such compositions further include a PBMC cell culture media. Furthermore, provided herein are methods for preparing freeze-dried PBMCs and for preparing rehydrated PBMCs, as well as methods for administering freeze-dried PBMCs.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The invention provides freeze-dried nucleated cells, a method for preparing them, and methods of using them for in vitro assays and in vivo therapeutic treatments. The method for preparing the cells includes incubating cells in the presence of a cryoprotective sugar to load them with the sugar, then lyophilizing them without separating the cells from the cryoprotective sugar. In embodiments, the cells are also loaded with one or more bioactive agents.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
Provided herein are methods and compositions for treating congenital hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
Provided herein are methods and compositions for treating acquired hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
Provided herein are methods and compositions for treating congenital hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
Provided herein are methods and compositions for treating acquired hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
Provided herein are methods and compositions for treating congenital hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
Provided herein are mRNA agent-loaded platelets, methods of preparing mRNA agent-loaded platelets, and methods of using mRNA agent-loaded platelets. In some embodiments, methods of loading mRNA agents into platelets include contacting platelets with an mRNA agent, a transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
A61K 49/06 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM]
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
Provided herein in some embodiments is a method of preparing a plasma product, including providing plasma, acidifying the plasma to form acidified plasma, drying the acidified plasma to form dried plasma, and milling the dried plasma to form a plasma product. Also provided are plasma products produced by the methods described herein.
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 31/7008 - Composés ayant un groupe amino lié directement à un atome de carbone du radical saccharide, p. ex. D-galactosamine, ranimustine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
57.
Thrombosomes as an antiplatelet agent reversal agent
In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
Provided herein in some embodiments is a method of treating a disease or condition such as an antibiotic resistant bacterial infection, a gram negative bacterial infection, a gram positive bacterial infection, a fungal infection, protozoa, a hemorrhagic virus, such as Ebola or Dengue, or a non-hemorrhagic virus, such as a coronavirus, in a subject, comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives, such as freeze-dried platelets; and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.
The present disclosure provides dry and liquid compositions that include canine platelets and/or canine platelet-derived substances in dried form or rehydrated form from a dried form of canine platelets and/or canine platelet-derived substances, as well as processes for preparing such compositions. The disclosure also provides processes for making the compositions and methods of using the compositions for therapeutic, prophylactic, diagnostic, and research purposes, and kits comprising the compositions.
A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cells for scientific, laboratory or medical research;
diagnostic, testing, and detection reagents comprising blood
platelets and other blood components for scientific,
laboratory or medical research. Adhesive bandages; bandages for skin wounds, surgical
bandages; blood platelets and other blood components for
medical use; chemical reagents comprising blood platelets
and other blood components for medical or veterinary
purposes; diagnostic reagents for clinical or medical
laboratory use, namely, compositions containing blood
platelets or other blood components.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cells for scientific, laboratory or medical research;
diagnostic, testing, and detection reagents comprising blood
platelets and other blood components for scientific,
laboratory or medical research. Adhesive bandages; bandages for skin wounds, surgical
bandages; blood platelets and other blood components for
medical use; chemical reagents comprising blood platelets
and other blood components for medical or veterinary
purposes; diagnostic reagents for clinical or medical
laboratory use, namely, compositions containing blood
platelets or other blood components.
Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 17/02 - Peptides immobilisés sur, ou dans, un support organique
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
Provided herein are mRNA agent-loaded platelets, methods of preparing mRNA agent-loaded platelets, and methods of using mRNA agent-loaded platelets. In some embodiments, methods of loading mRNA agents into platelets include treating platelets with an mRNA agent, a transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Cell culture reagents for scientific, laboratory or medical research purposes; Cell growth media for growing cells for use in scientific, laboratory or medical research; diagnostic, testing, and detection reagents comprising blood platelets and other blood components for scientific, laboratory or medical research.
(2) Blood platelets and other blood components for medical use; Blood products derived from non-human animals, namely, intravenously-administered blood substitutes for veterinary use containing freeze- dried blood plasma and rehydrated freeze- dried blood plasma to support normovolemia and normal coagulation status in non-human animals; Blood products derived from humans, namely, intravenously-administered blood substitutes for medical use containing freeze-dried blood plasma and rehydrated freeze-dried blood plasma to support normovolemia and normal coagulation status in humans; diagnostic reagents for clinical or medical laboratory use, namely, compositions containing blood platelets or other blood components.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Cell culture reagents for scientific, laboratory or medical research purposes; Cell growth media for growing cells for use in scientific, laboratory or medical research; diagnostic, testing, and detection reagents comprising blood platelets and other blood components for scientific, laboratory or medical research.
(2) Blood platelets and other blood components for medical use; Blood products derived from non-human animals, namely, intravenously-administered blood substitutes for veterinary use containing freeze-dried blood plasma and rehydrated freeze-dried blood plasma to support normovolemia and normal coagulation status in non-human animals; Blood products derived from humans, namely, intravenously-administered blood substitutes for medical use containing freeze-dried blood plasma and rehydrated freeze-dried blood plasma to support normovolemia and normal coagulation status in humans; diagnostic reagents for clinical or medical laboratory use, namely, compositions containing blood platelets or other blood components.
Provided herein is a composition of matter comprising dried blood plasma substantially free of blood cell components; and a) a resuscitative mixture comprising at least one saccharide, at least one salt, and at least one high molecular weight, non-ionic, hydrophilic polymer, b) platelets or platelet-derived material, or c) both a) and b).
This disclosure relates to a composition that, in some embodiments, includes cryopreserved platelets; and a cryoprotectant, wherein the composition comprises less than 6% (v/v) of dimethyl sulfoxide (DMSO). In some embodiments, the composition is substantially free of dimethyl sulfoxide (DMSO).
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 31/336 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à trois chaînons, p. ex. oxirane, fumagilline
77.
CRYOPRESERVED PLATELET COMPOSITIONS AND METHODS FOR MAKING
This disclosure relates to a composition that, in some embodiments, includes cryopreserved platelets; and a cryoprotectant, wherein the composition comprises less than 6% (v/v) of dimethyl sulfoxide (DMSO). In some embodiments, the composition is substantially free of dimethyl sulfoxide (DMSO).
This disclosure relates to a composition that, in some embodiments, includes cryopreserved platelets; and a cryoprotectant, wherein the composition comprises less than 6% (v/v) of dimethyl sulfoxide (DMSO). In some embodiments, the composition is substantially free of dimethyl sulfoxide (DMSO).
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Blood products derived from non-human animals for hemostatic
control, namely, compositions containing freeze-dried
platelets, cellular components of freeze-dried platelets,
rehydrated freeze-dried platelets, or rehydrated cellular
components of freeze-dried platelets for intravenous
administration to control hemostatic properties in non-human
animals. Research and development in the field of blood productions
for non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Blood products derived from non-human animals for hemostatic
control, namely, compositions containing freeze-dried
platelets, cellular components of freeze-dried platelets,
rehydrated freeze-dried platelets, or rehydrated cellular
components of freeze-dried platelets for intravenous
administration to control hemostatic properties in non-human
animals. Research and development in the field of blood productions
for non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood platelets and other blood components for medical use; chemical reagents comprising blood platelets and other blood components for medical or veterinary purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood platelets and other blood components for medical use; chemical reagents comprising blood platelets and other blood components for medical or veterinary purposes
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Cells for scientific, laboratory or medical research; diagnostic, testing, and detection kits comprising blood platelets and other blood components for scientific, laboratory or medical research; diagnostic reagents for clinical or medical laboratory use, namely, compositions containing blood platelets or other blood components
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Cells for scientific, laboratory or medical research; diagnostic, testing, and detection kits comprising blood platelets and other blood components for scientific, laboratory or medical research; diagnostic reagents for clinical or medical laboratory use, namely, compositions containing blood platelets or other blood components
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood products derived from non-human animals, namely,
intravenously-administered blood substitutes for veterinary
use containing freeze-dried blood plasma and rehydrated
freeze-dried blood plasma to support normovolemia and normal
coagulation status in non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood products for treatment of bleeding, namely,
compositions containing freeze-dried platelets or rehydrated
freeze-dried platelets to reduce bleeding in patients
suffering from a wound, patients undergoing surgery,
patients with a qualitative or quantitative platelet defect,
and patients taking platelet inhibiting medications.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Blood products derived from non-human animals for hemostatic control, namely, compositions containing freeze-dried platelets, cellular components of freeze-dried platelets, rehydrated freeze-dried platelets, or rehydrated cellular components of freeze-dried platelets for intravenous administration to control hemostatic properties in non-human animals. (1) Research and development in the field of blood productions for non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Blood products derived from non-human animals for hemostatic control, namely, compositions containing freeze-dried platelets, cellular components of freeze-dried platelets, rehydrated freeze-dried platelets, or rehydrated cellular components of freeze-dried platelets for intravenous administration to control hemostatic properties in non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Blood products derived from non-human animals, namely, intravenously-administered blood substitutes for veterinary use containing freeze-dried blood plasma and rehydrated freeze-dried blood plasma to support normovolemia and normal coagulation status in non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Biological preparations for the treatment of bleeding, namely, compositions containing freeze-dried platelets or rehydrated freeze-dried platelets to reduce bleeding in patients suffering from a wound, patients undergoing surgery, patients with a qualitative or quantitative platelet defect, and patients taking platelet inhibiting medications.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Blood products derived from non-human animals for hemostatic control, namely, compositions containing freeze-dried platelets, cellular components of freeze-dried platelets, rehydrated freeze-dried platelets, or rehydrated cellular components of freeze-dried platelets for intravenous administration to control hemostatic properties in non-human animals Research and development in the field of blood productions for non-human animals
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood products derived from non-human animals for hemostatic control, namely, compositions containing freeze-dried platelets, cellular components of freeze-dried platelets, rehydrated freeze-dried platelets, or rehydrated cellular components of freeze-dried platelets for intravenous administration to control hemostatic properties in non-human animals
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Blood products derived from non-human animals, namely, intravenously-administered blood platelet substitutes for veterinary use containing freeze-dried platelets, rehydrated freeze-dried platelets and cellular components thereof for reducing blood loss after trauma, promoting wound healing and controlling hemostatic properties in non-human animals
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Cell culture reagents for scientific, laboratory or medical research purposes; Chemical diagnostic reagents, diagnostic preparations, assay controls, and assays for medical and scientific research, namely, compositions containing blood platelets or other blood components; clinical diagnostic reagents, namely, compositions containing blood platelets or other blood components; Medical diagnostic reagents, Laboratory assays kits, solutions and compounds, namely, diagnostic reagents for medical diagnostic use, namely, compositions containing blood platelets or other blood components; medical diagnostic assays for testing blood, namely, compositions containing blood platelets or other blood components; Reagents for medical diagnostic purposes and assays kits for testing blood, namely, compositions containing blood platelets or other blood components; Diagnostic chemical reagents for medical purposes, namely, compositions containing blood platelets or other blood components; research laboratory analyzers for measuring, testing and analyzing blood type, namely, compositions containing blood platelets or other blood components; chemical reagents for medical and scientific purposes, namely, compositions containing blood platelets or other blood components; blood culture media for scientific purposes; blood grouping reagents, other than for medical purposes, namely, compositions containing blood platelets or other blood components; reagents for blood grouping for veterinary purposes, namely, compositions containing blood platelets or other blood components
(2) Adhesive bandages; bandages for skin wounds, surgical bandages; blood platelets and other blood components for medical use; diagnostic reagents for clinical or medical laboratory use, namely, compositions containing blood platelets or other blood components; Blood for medical purposes, namely, compositions containing blood platelets or other blood components; blood grouping reagents for medical purposes, namely, compositions containing blood platelets or other blood components; chemical reagents comprising blood components for medical and scientific purposes, namely, compositions containing blood platelets or other blood components; reagents for blood grouping for medical purposes, namely, compositions containing blood platelets or other blood components
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Blood products derived from non-human animals for hemostatic control, namely, blood substitutes, namely, compositions containing freeze-dried platelets, cellular components of freeze-dried platelets, rehydrated freeze-dried platelets, or rehydrated cellular components of freeze-dried platelets for intravenous administration to control hemostatic properties in non-human animals (1) Research and development in the field of blood productions for non-human animals.
The present disclosure provides dry and liquid compositions that include canine platelets and/or canine platelet-derived substances in dried form or rehydrated form from a dried form of canine platelets and/or canine platelet-derived substances, as well as processes for preparing such compositions. The disclosure also provides processes for making the compositions and methods of using the compositions for therapeutic, prophylactic, diagnostic, and research purposes, and kits comprising the compositions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Blood products derived from non-human animals for hemostatic
control, namely, compositions containing freeze-dried
platelets, cellular components of freeze-dried platelets,
rehydrated freeze-dried platelets, or rehydrated cellular
components of freeze-dried platelets for intravenous
administration to control hemostatic properties in non-human
animals. Research and development in the field of blood productions
for non-human animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Blood products derived from non-human animals, namely,
intravenously-administered blood platelet substitutes for
veterinary use containing freeze-dried platelets, rehydrated
freeze-dried platelets and cellular components thereof for
reducing blood loss after trauma, promoting wound healing
and controlling hemostatic properties in non-human animals.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cells for scientific, laboratory or medical research;
diagnostic, testing, and detection kits comprising blood
platelets and other blood components for scientific,
laboratory or medical research; chemical reagents comprising
blood platelets and other blood components. Adhesive bandages; bandages for skin wounds, surgical
bandages; blood platelets and other blood components for
medical use; diagnostic reagents for clinical or medical
laboratory use, namely, compositions containing blood
platelets or other blood components.
100.
COMPOSITIONS AND METHODS FOR TREATMENT OF LOSS OF FLUIDS LEADING TO HYPOTENSION AND/OR HYPOVOLEMIA
The present invention is directed to a composition containing at least one salt and at least one natural or synthetic high molecular weight, non-ionic, hydrophilic polymer. When in a liquid form, the composition is ready for infusion or injection to patients that suffer from loss of fluids that causes reduced volume and/or pressure in the systemic circulation. The composition is also suitable for treatment of organ conditions where blood flow is impaired or insufficient, resulting in organ distress, including tissue loss. The invention also relates to use as a prophylaxis to prevent medical consequences of anticipated conditions where depleted circulatory fluids, low blood pressure, or impaired organ perfusion require correction.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
